DFB Healthcare Acquisitions Corp. Share Price

Equities

Delayed Nasdaq Other stock markets 08:48:46 05/10/2021 pm IST			5-day change	1st Jan Change
23.49 ^USD	-0.29%		-0.88%	-37.27%

07/05	AdaptHealth's Shares Fall After Q1 Net Loss Misses Analysts' Forecast	MT
07/05	Earnings Flash (AHCO) ADAPTHEALTH Reports Q1 Revenue $792.5M, vs. Street Est of $769.9M	MT

Duration

Period

Style

AdaptHealth's Shares Fall After Q1 Net Loss Misses Analysts' Forecast	07/05	MT
Earnings Flash (AHCO) ADAPTHEALTH Reports Q1 Revenue $792.5M, vs. Street Est of $769.9M	07/05	MT
AdaptHealth Names Suzanne Foster as CEO	18/04	MT
UBS Adjusts AdaptHealth Price Target to $13 From $9, Maintains Buy Rating	28/02	MT
Deutsche Bank Adjusts AdaptHealth Price Target to $10 From $8, Maintains Hold Rating	28/02	MT
AdaptHealth's Q4 Loss Widens, Revenue Rises; Provides 2024 Revenue Guidance; Shares Climb	27/02	MT
Earnings Flash (AHCO) ADAPTHEALTH Posts Q4 Revenue $858.2M, vs. Street Est of $825.5M	27/02	MT
UBS Trims AdaptHealth Price Target to $9 From $10, Maintains Buy Rating	29/01	MT
UBS Adjusts AdaptHealth Price Target to $10 From $18, Maintains Buy Rating	08/11	MT
BofA Securities Downgrades AdaptHealth to Underperform From Neutral, Adjusts Price Target to $6.50 From $9.50	08/11	MT
AdaptHealth Facing Headwinds Due to Slower-Than-Expected Patient Transitions, BofA Says	08/11	MT
Deutsche Bank Adjusts AdaptHealth Price Target to $8 From $14, Maintains Hold Rating	08/11	MT
RBC Cuts Price Target on AdaptHealth to $13 From $18, Keeps Outperform Rating	08/11	MT
Earnings Flash (AHCO) ADAPTHEALTH Reports Q3 Revenue $804M, vs. Street Est of $796.6M	07/11	MT
BofA Securities Adjusts AdaptHealth's Price Target to $11 From $13, Keeps Neutral Rating	22/23/22	MT

UBS Adjusts AdaptHealth Price Target to $13 From $9, Maintains Buy Rating	28/02	MT
Deutsche Bank Adjusts AdaptHealth Price Target to $10 From $8, Maintains Hold Rating	28/02	MT
UBS Trims AdaptHealth Price Target to $9 From $10, Maintains Buy Rating	29/01	MT
UBS Adjusts AdaptHealth Price Target to $10 From $18, Maintains Buy Rating	08/11	MT
BofA Securities Downgrades AdaptHealth to Underperform From Neutral, Adjusts Price Target to $6.50 From $9.50	08/11	MT

AdaptHealth Corp. to Participate in the BofA Securities 2024 Health Care Conference	08/05	BU
AdaptHealth Corp. Announces First Quarter 2024 Results	07/05	BU
AdaptHealth Corp. Announces First Quarter 2024 Earnings Release Date and Conference Call	18/04	BU
AdaptHealth Appoints Suzanne Foster as Chief Executive Officer	18/04	BU
AdaptHealth Corp. Announces Fourth Quarter and Full-Year 2023 Results and Provides Initial 2024 Outlook	28/02	AQ